| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.02 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.02 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.083 | 0.03 |